Long‐term remission of extramedullary cutaneous relapse of acute myeloid leukaemia (leukaemia cutis) treated with decitabine‐venetoclax | Zendy

Maravalle Denise | Zendy; Filosa Alessandra | Zendy; Bigazzi Catia | Zendy; Collina Guido | Zendy; Galieni Piero | Zendy

Open Access

Long‐term remission of extramedullary cutaneous relapse of acute myeloid leukaemia (leukaemia cutis) treated with decitabine‐venetoclax

Author(s) -

Maravalle Denise,

Filosa Alessandra,

Bigazzi Catia,

Collina Guido,

Galieni Piero

Publication year - 2022

Publication title -

ejhaem

Language(s) - English

Resource type - Journals

ISSN - 2688-6146

DOI - 10.1002/jha2.388

Subject(s) - decitabine , medicine , venetoclax , leukemia cutis , cytarabine , oncology , regimen , myeloid , cd33 , myeloid leukemia , leukemia , gastroenterology , biochemistry , gene expression , chemistry , chronic lymphocytic leukemia , dna methylation , gene , genetics , stem cell , biology , cd34

In February 2020, a 74‐year‐old female was diagnosed with myelomonocytic acute myeloid leukaemia with FLT3 mutation and blasts positive for CD33, BCL‐2 and CD68/PGM1. Not responding to a standard Cytarabine–containing regimen plus Midostaurin, the patient achieved a complete remission (CR) of the disease in the bone marrow following a reinduction therapy with high‐dose Cytarabine but simultaneously relapsed developing leukaemia cutis with disseminated lesions in 80% of the body surface area. After receiving 10 cycles of Decitabine plus Venetoclax the patient achieved and maintains a continuous CR.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research